Back to top

gene-editing: Archive

Ahan Chakraborty

What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.

SNYNegative Net Change NVONegative Net Change LLYNegative Net Change

Sundeep Ganoria

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.

NVSNegative Net Change BMYNegative Net Change VRTXNegative Net Change BEAMNegative Net Change CRSPNegative Net Change

Ekta Bagri

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

LLYNegative Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change

Zacks Equity Research

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.

SNYNegative Net Change BMYNegative Net Change LLYNegative Net Change

Zacks Equity Research

SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion

Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.

RHHBYNegative Net Change SRPTNegative Net Change AGENNegative Net Change IMCRPositive Net Change

Sundeep Ganoria

CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?

CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.

VRTXNegative Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change